- Home
- GECC vs AGEN Comparison
GECC vs AGEN Comparison
Compare GECC & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GECC
- AGEN
- Stock Information
- Founded
- GECC 2016
- AGEN 1994
- Country
- GECC United States
- AGEN United States
- Employees
- GECC N/A
- AGEN N/A
- Industry
- GECC Finance: Consumer Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GECC Finance
- AGEN Health Care
- Exchange
- GECC Nasdaq
- AGEN Nasdaq
- Market Cap
- GECC 106.1M
- AGEN 96.2M
- IPO Year
- GECC N/A
- AGEN 2000
- Fundamental
- Price
- GECC $10.34
- AGEN $2.83
- Analyst Decision
- GECC
- AGEN Buy
- Analyst Count
- GECC 0
- AGEN 3
- Target Price
- GECC N/A
- AGEN $10.50
- AVG Volume (30 Days)
- GECC 28.3K
- AGEN 566.5K
- Earning Date
- GECC 10-31-2024
- AGEN 11-12-2024
- Dividend Yield
- GECC 13.47%
- AGEN N/A
- EPS Growth
- GECC N/A
- AGEN N/A
- EPS
- GECC 0.65
- AGEN N/A
- Revenue
- GECC $39,468,000.00
- AGEN $160,427,000.00
- Revenue This Year
- GECC $18.56
- AGEN N/A
- Revenue Next Year
- GECC $5.85
- AGEN $36.13
- P/E Ratio
- GECC $15.97
- AGEN N/A
- Revenue Growth
- GECC 16.86
- AGEN 59.00
- 52 Week Low
- GECC $9.55
- AGEN $2.50
- 52 Week High
- GECC $11.31
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- GECC 57.69
- AGEN 39.40
- Support Level
- GECC $9.96
- AGEN $2.65
- Resistance Level
- GECC $10.74
- AGEN $3.85
- Average True Range (ATR)
- GECC 0.24
- AGEN 0.29
- MACD
- GECC 0.00
- AGEN -0.02
- Stochastic Oscillator
- GECC 76.86
- AGEN 15.00
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. The company seeks to generate current income and capital appreciation through debt and equity investments, including investments in specialty finance businesses. It invests in senior secured and senior unsecured debt instruments, as well as in junior loans and mezzanine debt of middle-market companies and small businesses. The company generates revenue from interest on the debt investments that it holds.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).